Virios Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 1, 2024

DWTX$1.23+2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2023 and 2022

BALANCE SHEETS


	2023		2022

Assets · ·
Current assets: · ·
Cash		$3,316,946		$7,030,992
Prepaid expenses and other current assets		848,496		1,338,764
Total current assets		4,165,442		8,369,756
Total assets		$4,165,442		$8,369,756
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$111,913		$573,164
Accrued expenses		246,635		470,098
Total current liabilities		358,548		1,043,262
Total liabilities		358,548		1,043,262
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, $0.0001 par value; 43,000,000 shares authorized; 19,450,888 and 19,257,937 shares issued and outstanding at December 31, 2023, respectively; and 18,330,390 shares issued and outstanding at December 31, 2022		1,926		1,833
Preferred stock, $0.0001 par value; 2,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022		—		—
Additional paid-in capital		65,573,300		63,497,868
Accumulated deficit		(61,469,222)		(56,173,207)
		4,106,004		7,326,494
Less: Treasury stock, 192,951 shares of common stock at cost		(299,110)		—
Total stockholders' equity		3,806,894		7,326,494
Total liabilities and stockholders' equity		$4,165,442		$8,369,756

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.